Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marianne Andersen

Showing results (41-50 of 127) with videos related to

Pageof 13
Sort By:
The Journal of Clinical Endocrinology and Metabolism|April 19, 2014
Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndromeDorte Glintborg, Magda Lambaa Altinok, Hanne Mumm, et al.
Diabetes Care|November 15, 2007
Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatmentDorte Glintborg, Kurt Højlund, Marianne Andersen, et al.
Human Reproduction (Oxford, England)|March 25, 2016
Prevalence and possible mechanisms of reactive hypoglycemia in polycystic ovary syndromeHanne Mumm, Magda Lambaa Altinok, Jan Erik Henriksen, et al.
Diabetes, Obesity & Metabolism|June 7, 2016
Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapyLine V Magnussen, Dorte Glintborg, Pernille Hermann, et al.
Journal of Endocrinological Investigation|June 8, 2014
Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndromeDorte Glintborg, Hanne Mumm, Magda Lambaa Altinok, et al.
Endocrine Connections|February 24, 2018
Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOSDorte Glintborg, Magda Lambaa Altinok, Pernille Ravn, et al.
Ugeskrift for Laeger|January 22, 2010
[Endocrinological assessment, treatment and follow-up on polycystic ovary syndrome]Dorte Glintborg, Jørgen Rungby, Peter Eskildsen, et al.
Acta Obstetricia Et Gynecologica Scandinavica|February 13, 2020
Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndromeAnne C M Godtfredsen, Johannes J Sidelmann, Jørgen B Gram, et al.
European Journal of Endocrinology|July 27, 2006
Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controlsDorte Glintborg, Marianne Andersen, Claus Hagen, et al.
Experimental Gerontology|April 20, 2016
Voluntary muscle activation improves with power training and is associated with changes in gait speed in mobility-limited older adults - A randomized controlled trialLars G Hvid, Elsa S Strotmeyer, Mathias Skjødt, et al.
Pageof 13

Showing results (41-50 of 127) with videos related to

Sort By:
Pageof 13
The Journal of Clinical Endocrinology and Metabolism|April 19, 2014
Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndromeDorte Glintborg, Magda Lambaa Altinok, Hanne Mumm, et al.
Diabetes Care|November 15, 2007
Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatmentDorte Glintborg, Kurt Højlund, Marianne Andersen, et al.
Human Reproduction (Oxford, England)|March 25, 2016
Prevalence and possible mechanisms of reactive hypoglycemia in polycystic ovary syndromeHanne Mumm, Magda Lambaa Altinok, Jan Erik Henriksen, et al.
Diabetes, Obesity & Metabolism|June 7, 2016
Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapyLine V Magnussen, Dorte Glintborg, Pernille Hermann, et al.
Journal of Endocrinological Investigation|June 8, 2014
Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndromeDorte Glintborg, Hanne Mumm, Magda Lambaa Altinok, et al.
Endocrine Connections|February 24, 2018
Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOSDorte Glintborg, Magda Lambaa Altinok, Pernille Ravn, et al.
Ugeskrift for Laeger|January 22, 2010
[Endocrinological assessment, treatment and follow-up on polycystic ovary syndrome]Dorte Glintborg, Jørgen Rungby, Peter Eskildsen, et al.
Acta Obstetricia Et Gynecologica Scandinavica|February 13, 2020
Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndromeAnne C M Godtfredsen, Johannes J Sidelmann, Jørgen B Gram, et al.
European Journal of Endocrinology|July 27, 2006
Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controlsDorte Glintborg, Marianne Andersen, Claus Hagen, et al.
Experimental Gerontology|April 20, 2016
Voluntary muscle activation improves with power training and is associated with changes in gait speed in mobility-limited older adults - A randomized controlled trialLars G Hvid, Elsa S Strotmeyer, Mathias Skjødt, et al.
Pageof 13